Publication Date:
2009
Citation:
Proteina C reattiva e statine per la prevenzione primaria della coronaropatia / M. Panteghini. - In: BIOCHIMICA CLINICA. - ISSN 0393-0564. - 33:3(2009), pp. 165-167.
abstract:
C-reactive protein and statins for primary prevention of coronary heart disease. A slight increase in the serum
concentration of C-reactive protein (CRP) has been associated with an increased risk of coronary heart disease. The recently published and widely publicized results of the JUPITER study have confirmed the role of CRP as risk biomarker, suggesting the use of the protein determination as a means to modulate the primary prevention treatment.
As a result, it is anticipated that many apparently healthy persons will ask for the CRP measurement in order to test their risk and, in case, start a statin therapy, with a consequent great increase in CRP testing. In this context clinical laboratories need to stay on top of the issues related to this biomarker, playing a key role in ensuring the test is ordered and employed correctly by focusing on its advantages and limitations
concentration of C-reactive protein (CRP) has been associated with an increased risk of coronary heart disease. The recently published and widely publicized results of the JUPITER study have confirmed the role of CRP as risk biomarker, suggesting the use of the protein determination as a means to modulate the primary prevention treatment.
As a result, it is anticipated that many apparently healthy persons will ask for the CRP measurement in order to test their risk and, in case, start a statin therapy, with a consequent great increase in CRP testing. In this context clinical laboratories need to stay on top of the issues related to this biomarker, playing a key role in ensuring the test is ordered and employed correctly by focusing on its advantages and limitations
IRIS type:
01 - Articolo su periodico
List of contributors:
M. Panteghini
Link to information sheet: